Risks
4 risks
Risk Intelligence
US FDA inspection outcomes
View Risks →Biocon Limited — Q1 FY25
Biocon's Q1 FY25 revenue from operations was flat YoY at INR 3,433 crore, with adjusted EBITDA of INR 698 crore (20% margin) and adjusted PAT of INR 19 crore.
neutral
medium
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Biocon's Q1 FY25 revenue from operations was flat YoY at INR 3,433 crore, with adjusted EBITDA of INR 698 crore (20% margin) and adjusted PAT of INR 19 crore. The biosimilars segment grew 11% like-for-like, offsetting declines in generics (-6%) and Syngene (-2%). The Eris Lifesciences transaction contributed INR 1,057 crore as other income. Management expects Q2 to mirror Q1, with a transition to accelerated growth in H2 driven by new product launches (liraglutide, ustekinumab) and biosimilar momentum. Key risks include US FDA inspection outcomes at Bengaluru facilities (10 observations) and ongoing litigation for aflibercept launch timing.
बायोकॉन की पहली तिमाही (अप्रैल-जून 2024) की कमाई पिछले साल के मुकाबले लगभग बराबर रही, जो 3,433 करोड़ रुपये थी। कंपनी ने 698 करोड़ रुपये का एडजस्टेड EBITDA (कमाई में से कुछ खर्चे निकालने के बाद का मुनाफा) कमाया, जो 20% मार्जिन है। शुद्ध मुनाफा सिर्फ 19 करोड़ रुपये रहा। बायोसिमिलर (महंगी दवाओं के सस्ते विकल्प) सेगमेंट में 11% बढ़ोतरी हुई, जबकि जेनेरिक दवाओं में 6% और सिंजीन में 2% गिरावट आई। एरिस लाइफसाइंसेज से हुए सौदे से 1,057 करोड़ रुपये की अतिरिक्त आय मिली। कंपनी को उम्मीद है कि दूसरी तिमाही भी पहली जैसी रहेगी, लेकिन साल की दूसरी छमाही में नई दवाओं (जैसे लिराग्लूटाइड, उस्टेकिनुमैब) के लॉन्च से तेजी आएगी। जोखिमों में अमेरिकी FDA की बेंगलुरु फैक्ट्री की जांच (10 कमियां) और एफ्लिबरसेप्ट दवा के लॉन्च पर कानूनी लड़ाई शामिल है।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Biosimilars like-for-like revenue growth
11%
+11% YoY
Biosimilars revenue from operations grew 11% on a like-for-like basis, driven by strong US and emerging market performance.
Fulphila US market share
20%
Stable
Fulphila (pegfilgrastim) holds a 20% market share in the US, supported by new market access agreements.
Syngene RFP growth
50%
+50% YoY
Syngene saw a 50% year-on-year increase in requests for proposals, indicating a recovery in biotech funding.
Net debt at BBL
$1.2B
Sequentially improved
Net debt at Biocon Biologics stood at approximately $1.2 billion, with working capital efficiencies driving sequential improvement.
What Changed vs Last Quarter
NEW
Ustekinumab launch in Q4 FY25
Biocon expects to launch ustekinumab (Stelara biosimilar) in the US in the last quarter of FY25, subject to FDA approval and settlement agreements.
NEW
Debt reduction priority
Management intends to reduce debt further during FY25, following a $250 million reduction last year, but no specific timeline or amount was provided.
UPDATED
H2 FY25 growth acceleration
Management expects Q2 to be similar to Q1, with a transition to accelerated growth in the second half of FY25, driven by biosimilars traction, new generic launches, and Syngene momentum.
UPDATED
Generics high single-digit growth for FY25
Generics business is expected to deliver high single-digit revenue growth for the full year, with H2 significantly stronger than H1.
DROPPED
Syngene FY25 revenue growth: single-digit to low double-digit
Syngene expects constant currency revenue growth of single-digit to low double-digit in FY25.
DROPPED
Syngene FY25 EBITDA margin similar to FY24
Syngene expects operating EBITDA margin to be similar to FY24 levels (~31%).
DROPPED
Biosimilars R&D spend 8%-9% of revenues
Biocon Biologics expects R&D investments to be in the 8%-9% of revenues range.
NEW RISK
Aflibercept litigation delays
Ongoing patent litigation with the innovator in the US may delay commercialization of aflibercept, despite FDA approval and interchangeable status.
NEW RISK
Debt servicing and refinancing risk
Net debt at BBL is ~$1.2 billion; while management is exploring options, no specific deleveraging plan was disclosed, raising concerns about interest costs.
RISK GONE
Delayed U.S. adalimumab market opening
Biosimilar adalimumab market in the U.S. is not expected to materially open until calendar 2025, delaying revenue contribution.
RISK GONE
Debt reduction uncertainty
Management declined to provide specific quantitative guidance on debt reduction, raising concerns about pace and magnitude.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q2 FY24, Q3 FY24
The U.S. Adalimumab biosimilar market is expected to open meaningfully only in CY2025, delaying potential revenue contribution from this large opportunity.
Mentioned in Q1 FY24, Q2 FY24
Net debt to EBITDA elevated; interest costs rising due to high rate environment; deferred payments in FY25 may require additional funding.
Mentioned in Q1 FY24, Q2 FY24
Syngene is expected to deliver mid-teen constant currency growth for the full year, supported by strong performance in development and manufacturing services.
Fast read
Guidance and risk preview
Management expects Q2 to be similar to Q1, with a transition to accelerated growth in the second half of FY25, driven by biosimilars traction, new...
The US FDA issued 10 observations (Form 483) at Biocon Park facilities in Bengaluru; while procedural, resolution timing is uncertain and could imp...
View Risks →